BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC.
Laboratory Analytical Instruments · OTC · SEC CIK 1310488 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY75.0%
TTM EPS YoY80.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-44.3%
ROA-28.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-17.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $66,951 | $67,437 |
| Pretax income | -$489,951 | -$490,437 |
| Net income | -$1.29M | -$490,437 |
| EPS (basic) | -0.04 | -0.02 |
| EPS (diluted) | -0.04 | -0.02 |
| Weighted avg. shares (diluted) | 33.21M | 29.27M |
| Balance sheet | ||
| Cash & equivalents | $786 | $862 |
| Current assets | $786 | $862 |
| Total assets | $786 | $862 |
| Current liabilities | $619,329 | $2.30M |
| Total liabilities | $619,329 | $2.30M |
| Shareholders' equity | -$618,543 | -$2.30M |
| Shares outstanding | 33.52M | 29.27M |
| Cash flow statement | ||
| Operating cash flow | -$65,150 | -$61,250 |
| Financing cash flow | $65,074 | $61,474 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.